Alnylam Pharmaceuticals Inc (A1LN34)
BOV
News
Market Data
Register for real-time alerts, custom portfolio, and market movers
The current A1LN34 market cap is 10.3B. The company's latest EPS is USD -3.5081 and P/E is -79.48.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 750.53M | 439.72M | 494.33M | 659.83M | 500.92M |
| Operating Income | 213.87M | -116.4M | -43.44M | 48.61M | -76.91M |
| Net Income | 147.75M | -137.87M | -65.94M | -16.89M | -111.57M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 219.75M | 492.85M | 844.29M | 1.04B | 1.83B |
| Operating Income | -939.43M | -828.44M | -708.65M | -785.07M | -282.18M |
| Net Income | -886.12M | -858.28M | -852.82M | -1.13B | -440.24M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 3.84B | 3.83B | 3.82B | 4.01B | 4.21B |
| Total Liabilities | 4B | 4.05B | 4.04B | 4.01B | 4.17B |
| Total Equity | -165.87M | -220.64M | -219.27M | -3.07M | 32.35M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 2.4B | 3.41B | 3.64B | 3.55B | 3.83B |
| Total Liabilities | 956.44M | 2.39B | 3.06B | 3.7B | 4.05B |
| Total Equity | 1.44B | 1.02B | 588.2M | -158.22M | -220.64M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 133.95M | 104.16M | -81.52M | 42.64M | 86.35M |
| Investing | -95.69M | -336.35M | -67.62M | -33.68M | -63.93M |
| Financing | 132.9M | 172.13M | 28.91M | 160.41M | 263.16M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -278.43M | -614.96M | -641.69M | -541.27M | 104.16M |
| Investing | -417.68M | -435.52M | -273.3M | 169.35M | -336.35M |
| Financing | 823.18M | 994.98M | 1.25B | 425.75M | 172.13M |
| Market Cap | 10.3B |
| Price to Earnings Ratio | -79.48 |
| Price to Sales Ratio | 19.14 |
| Price to Cash Ratio | 43.05 |
| Price to Book Ratio | -158.58 |
| Dividend Yield | - |
| Shares Outstanding | 125.49M |
| Average Volume (1 week) | 96 |
| Average Volume (1 Month) | 230 |
| 52 Week Change | 86.63% |
| 52 Week High | 85.44 |
| 52 Week Low | 36.23 |
| Spread (Intraday) | 72.35 (87.86%) |
| Company Name | Alnylam Pharmaceuticals Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.alnylam.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
